# Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy

> **NCT01732146** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 120 (actual)

## Conditions studied

- Hypoxic Ischemic Encephalopathy

## Interventions

- **DRUG:** erythropoietin Beta
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01732146
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-28
- **Primary completion:** 2017-02-14
- **Final completion:** 2017-02-14
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732146, "Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01732146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*